195 related articles for article (PubMed ID: 18757082)
21. Epigenetic abnormalities in cutaneous squamous cell carcinomas: frequent inactivation of the RB1/p16 and p53 pathways.
Murao K; Kubo Y; Ohtani N; Hara E; Arase S
Br J Dermatol; 2006 Nov; 155(5):999-1005. PubMed ID: 17034532
[TBL] [Abstract][Full Text] [Related]
22. Immunohistochemically detected p53 and HER-2/neu expression and nuclear DNA content in familial epithelial ovarian carcinomas.
Auranen A; Grénman S; Kleml PJ
Cancer; 1997 Jun; 79(11):2147-53. PubMed ID: 9179061
[TBL] [Abstract][Full Text] [Related]
23. p53 mutations and overexpression affect prognosis of ovarian endometrioid cancer but not clear cell cancer.
Okuda T; Otsuka J; Sekizawa A; Saito H; Makino R; Kushima M; Farina A; Kuwano Y; Okai T
Gynecol Oncol; 2003 Mar; 88(3):318-25. PubMed ID: 12648581
[TBL] [Abstract][Full Text] [Related]
24. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer.
Berry DA; Muss HB; Thor AD; Dressler L; Liu ET; Broadwater G; Budman DR; Henderson IC; Barcos M; Hayes D; Norton L
J Clin Oncol; 2000 Oct; 18(20):3471-9. PubMed ID: 11032587
[TBL] [Abstract][Full Text] [Related]
25. In microdissected ductal carcinoma in situ, HER-2/neu amplification, but not p53 mutation, is associated with high nuclear grade and comedo histology.
Ho GH; Calvano JE; Bisogna M; Borgen PI; Rosen PP; Tan LK; Van Zee KJ
Cancer; 2000 Dec; 89(11):2153-60. PubMed ID: 11147584
[TBL] [Abstract][Full Text] [Related]
26. p53 gene mutations and protein accumulation in human ovarian cancer.
Kupryjańczyk J; Thor AD; Beauchamp R; Merritt V; Edgerton SM; Bell DA; Yandell DW
Proc Natl Acad Sci U S A; 1993 Jun; 90(11):4961-5. PubMed ID: 8506342
[TBL] [Abstract][Full Text] [Related]
27. DNA demethylase is expressed in ovarian cancers and the expression correlates with demethylation of CpG sites in the promoter region of c-erbB-2 and survivin genes.
Hattori M; Sakamoto H; Satoh K; Yamamoto T
Cancer Lett; 2001 Aug; 169(2):155-64. PubMed ID: 11431104
[TBL] [Abstract][Full Text] [Related]
28. Elevated cyclooxygenase-2 expression is associated with altered expression of p53 and SMAD4, amplification of HER-2/neu, and poor outcome in serous ovarian carcinoma.
Erkinheimo TL; Lassus H; Finne P; van Rees BP; Leminen A; Ylikorkala O; Haglund C; Butzow R; Ristimäki A
Clin Cancer Res; 2004 Jan; 10(2):538-45. PubMed ID: 14760075
[TBL] [Abstract][Full Text] [Related]
29. Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo.
Concin N; Hofstetter G; Berger A; Gehmacher A; Reimer D; Watrowski R; Tong D; Schuster E; Hefler L; Heim K; Mueller-Holzner E; Marth C; Moll UM; Zeimet AG; Zeillinger R
Clin Cancer Res; 2005 Dec; 11(23):8372-83. PubMed ID: 16322298
[TBL] [Abstract][Full Text] [Related]
30. Breast cancer DNA methylation profiles in cancer cells and tumor stroma: association with HER-2/neu status in primary breast cancer.
Fiegl H; Millinger S; Goebel G; Müller-Holzner E; Marth C; Laird PW; Widschwendter M
Cancer Res; 2006 Jan; 66(1):29-33. PubMed ID: 16397211
[TBL] [Abstract][Full Text] [Related]
31. Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and Her-2/neu expression in ovarian cancer.
Ferrandina G; Ranelletti FO; Lauriola L; Fanfani F; Legge F; Mottolese M; Nicotra MR; Natali PG; Zakut VH; Scambia G
Gynecol Oncol; 2002 May; 85(2):305-10. PubMed ID: 11972392
[TBL] [Abstract][Full Text] [Related]
32. Cyclin D1 overexpression and p53 mutation status in epithelial ovarian cancer.
Shigemasa K; Tanimoto H; Parham GP; Parmley TH; Ohama K; O'Brien TJ
J Soc Gynecol Investig; 1999; 6(2):102-8. PubMed ID: 10205781
[TBL] [Abstract][Full Text] [Related]
33. Methylation in the p53 promoter in epithelial ovarian cancer.
Chmelarova M; Krepinska E; Spacek J; Laco J; Beranek M; Palicka V
Clin Transl Oncol; 2013 Feb; 15(2):160-3. PubMed ID: 22855178
[TBL] [Abstract][Full Text] [Related]
34. Four tumour markers for urinary bladder cancer--tissue polypeptide antigen (TPA), HER-2/neu (ERB B2), urokinase-type plasminogen activator receptor (uPAR) and TP53 mutation.
Ecke TH; Schlechte HH; Schulze G; Lenk SV; Loening SA
Anticancer Res; 2005; 25(1B):635-41. PubMed ID: 15816639
[TBL] [Abstract][Full Text] [Related]
35. Is it possible to diagnose malignancy from fluid in cystic ovarian tumors?
Yamada R; Maeda N; Oguri H; Adachi Y; Takeuchi T; Furihata M; Fukaya T
Eur J Obstet Gynecol Reprod Biol; 2013 Nov; 171(1):96-100. PubMed ID: 24017961
[TBL] [Abstract][Full Text] [Related]
36. Contribution of c-erbB-2 and topoisomerase IIalpha to chemoresistance in ovarian cancer.
Hengstler JG; Lange J; Kett A; Dornhöfer N; Meinert R; Arand M; Knapstein PG; Becker R; Oesch F; Tanner B
Cancer Res; 1999 Jul; 59(13):3206-14. PubMed ID: 10397267
[TBL] [Abstract][Full Text] [Related]
37. p53 mutations in benign breast tissue.
Millikan R; Hulka B; Thor A; Zhang Y; Edgerton S; Zhang X; Pei H; He M; Wold L; Melton LJ
J Clin Oncol; 1995 Sep; 13(9):2293-300. PubMed ID: 7666086
[TBL] [Abstract][Full Text] [Related]
38. Assessment of p53 and HER-2/neu genes status and protein products in oral squamous cell carcinomas.
Stoicănescu D; Andreescu N; Belengeanu A; Meszaros N; Cornianu M
Rom J Morphol Embryol; 2013; 54(4):1107-13. PubMed ID: 24399009
[TBL] [Abstract][Full Text] [Related]
39. Expression of p53 and HER2/Neu in Kenyan Women With Primary Ovarian Carcinoma.
Mutuiri AP; Nzioka A; Busarla SV; Sayed S; Moloo Z
Int J Gynecol Pathol; 2016 Nov; 35(6):537-543. PubMed ID: 26825003
[TBL] [Abstract][Full Text] [Related]
40. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer.
Reles A; Wen WH; Schmider A; Gee C; Runnebaum IB; Kilian U; Jones LA; El-Naggar A; Minguillon C; Schönborn I; Reich O; Kreienberg R; Lichtenegger W; Press MF
Clin Cancer Res; 2001 Oct; 7(10):2984-97. PubMed ID: 11595686
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
